Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 5/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | WEE1 | P30291 | 2/20 | 0.38 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5304399 | 0.86 | EPHB4 (0.43) | EPHB4ELANEPARP1DHODHACHE | |
| SCHEMBL10258857 | 0.85 | PDE10A (0.54) | TP53HSD17B10HTTELANEPARP1 | |
| SCHEMBL28881597 | 0.81 | DHODH (0.51) | EPHB4PDE10ADHODHKDM4EMEN1 | |
| SCHEMBL28386669 | 0.79 | ELANE (0.42) | EPHB4ELANEPARP1DHODHACHE | |
| SCHEMBL14883918 | 0.77 | HTT (0.69) | TP53HSD17B10HTTPDE10ADHODH | |
| SCHEMBL8168011 | 0.76 | PDE10A (0.47) | EPHB4TP53HSD17B10HTTPDE10A | |
| SCHEMBL618719 | 0.76 | HSD17B10 (0.53) | TP53HSD17B10HTTELANEPARP1 | |
| SCHEMBL29041769 | 0.75 | ELANE (0.42) | EPHB4ELANEPARP1DHODHACHE | |
| SCHEMBL3885065 | 0.75 | ELANE (0.47) | ELANEPARP1ACHE | |
| SCHEMBL29791541 | 0.75 | ELANE (0.47) | ELANEPARP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, SNRPE, DDX21 | EPHB4 3431/4885TP53 333/4885HSD17B10 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.